• Hyperion Therapeutics Inc., of South San Francisco, reported net revenue of $7.3 million following the first full quarter of sales of its newly approved compound, Ravicti (glycerol phenylbutyrate) oral liquid, and one month of sales of Buphenyl (sodium phenylbutyrate) tablets and powder following the company's acquisition of that product.